The short version of adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-04. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== Traditional and alternative uses == The medicinal uses of insects and other arthropods worldwide have been reviewed by Meyer-Rochow, who provides examples of all major insect groups, spiders, worms and molluscs and discusses their potential as suppliers of bioactive components. Using insects (and spiders) to treat various maladies and injuries has a long tradition and, having stood the test of time, can be effective and provide results. However, sometimes folk-medicinal "logic" was based on the Doctrine of Signatures ("let likes be cured by likes") and had, if any at all, little more than a psychological effect. For example, to treat cases of constipation, dung beetles were prescribed; to slim down stick insects were thought to help; hairy tarantulas seemed the right treatment for hair loss and fat grubs resembling the swollen limb caused by the parasite Wuchereria bancrofti were expected to help the elephantiasis patient. An organism bearing parts that resemble human body parts, animals, or other objects, was thought to have useful relevance to those parts, animals or objects. So, for example, the femurs of grasshoppers, which were said to resemble the human liver, were used to treat liver ailments by the indigenous peoples of Mexico. This doctrine is common throughout traditional and alternative medicine, but is most prominent where medical traditions are broadly accepted, as in traditional Chinese medicine and Ayurveda, and less by community and family based medicine, as is more common in parts of Africa.
Fish and shellfish have a natural tendency to concentrate inorganic and organic toxins and pollutants in their bodies, including methylmercury, a highly toxic organic compound of mercury, polychlorinated biphenyls (PCBs), and microplastics. Species of fish that are high on the food chain, such as shark, swordfish, king mackerel, albacore tuna, and tilefish contain higher concentrations of these bioaccumulates. This is because bioaccumulates are stored in the muscle tissues of fish, and when a predatory fish eats another fish, it assumes the entire body burden of bioaccumulates in the consumed fish. Thus species that are high on the food chain amass body burdens of bioaccumulates that can be ten times higher than the species they consume. This process is called biomagnification. Man-made disasters can cause localized hazards in seafood which may spread widely via piscine food chains. The first occurrence of widespread mercury poisoning in humans occurred this way in the 1950s in Minamata, Japan. Wastewater from a nearby chemical factory released methylmercury that accumulated in fish which were consumed by humans. Severe mercury poisoning is now known as Minamata disease. The 2011 Fukushima Daiichi Nuclear Power Plant disaster and 1947–1991 Marshall Islands nuclear bomb testing led to dangerous radionuclide contamination of local sea life which, in the latter case, remained as of 2008.
== Personnel == Fishbone Angelo Moore – saxophone, vocals Walter A. Kibby II – trumpet, vocals Kendall Jones – guitars, vocals Chris Dowd – keyboards, trombone, vocals John Norwood Fisher – bass, vocals Philip "Fish" Fisher – drums Additional personnel Lisa Grant – vocals on "Lyin' Ass Bitch" Production Nancy Donald – design David Kahne – engineer Tony Lane – design David Leonard – engineer, mixing John Scarpati – photography Jack Skinner – mastering (Sterling Sound, New York City)
== See also == Adipose tissue Appetite Basal metabolic rate Energy homeostasis Glucagon Glycemic index Glycemic load Hyperinsulinemia Insulin sensitivity Insulin Ketogenic diet Leptin Lipogenesis Low-carbohydrate diet Low-glycemic index diet Metabolic Syndrome Obesity Refined carbohydrates Set point theory Sugar Ultra-processed food
Sources: en.wikipedia.org
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth. Development by Boehringer Ingelheim was halted in October 2010, following a negative evaluation by the US Food and Drug Administration (FDA). The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015. Addyi is approved for medical use in the United States for premenopausal women with hypoactive sexual desire disorder and in Canada for premenopausal and postmenopausal women with hypoactive sexual desire disorder. Hypoactive sexual desire disorder was recognized as a distinct sexual function disorder for more than 30 years, but was removed from the Diagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis called female sexual interest/arousal disorder (FSIAD).
=== 1981 === January 17: Martial law was lifted by Ferdinand Marcos in preparation for the visit of Pope John Paul II. January 20: Ronald Reagan inaugurated 40th President of the United States. Reagan is elected on a platform opposed to the concessions of détente. Also that day the Iran hostage crisis ends. March 30: Two months after his inauguration Ronald Reagan is shot in the chest while leaving a Washington hotel. The gunman, John Hinckley, is found to be mentally unhinged and obsessed with actress Jodie Foster. April 1: The United States suspends economic aid to Nicaragua. April 6: The Somaliland War of Independence was waged by the Somali National Movement in northern Somalia. May 13: While riding in an open-topped car through the Vatican, Pope John Paul II is shot four times in the abdomen and right arm. The gunman, Mehmet Ali Agca, is a Turkish Kurd with uncertain motives. August 19: Gulf of Sidra Incident: Libyan planes attack U.S. jets in the Gulf of Sidra, which Libya has illegally annexed. Two Libyan jets are shot down; no American losses are suffered. September 21: Belize becomes independent from the UK. 1,500 British soldiers remain to deter Guatemala from attacking the country over territorial disputes. October 6: President Anwar Sadat of Egypt is shot and killed in Cairo during the annual victory parade. October 27: A Soviet submarine, the U137, runs aground not far from the Swedish naval base at Karlskrona. November 23: The U.S. Central Intelligence Agency (CIA) begins to support anti-Sandinista Contras. December 13: Gen.
Cloning of the YAP1 gene facilitated the identification of a modular protein domain, known as the WW domain. Two splice isoforms of the YAP1 gene product were initially identified, named YAP1-1 and YAP1-2, which differed by the presence of an extra 38 amino acids that encoded the WW domain. Apart from the WW domain, the modular structure of YAP1 contains a proline-rich region at the very amino terminus, which is followed by a TID (TEAD transcription factor interacting domain). Next, following a single WW domain, which is present in the YAP1-1 isoform, and two WW domains, which are present in the YAP1-2 isoform, there is the SH3-BM (Src Homology 3 binding motif). Following the SH3-BM is a TAD (transactivation domain) and a PDZ domain-binding motif (PDZ-BM) (Figure 1).
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.